Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study
Journal of Clinical Oncology · 10.06.2026 · 44 (17) · 1624-1634
DOI: 10.1200/jco-25-02187 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.06.2026. Verfasst von Paul E Oberstein und 45 weiteren Autor:innen. Beteiligte Einrichtung: NYU Langone Health, New York, NY. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antibodies, Bispecific, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Amivantamab, an EGFR-MET bispecific antibody with immune cell–directing activity, is approved in non–small cell lung cancer (NSCLC). Effective treatments are limited for chemorefractory metastatic colorectal cancer (mCRC). METHODS OrigAMI-1 (ClinicalTrials.gov identifier: NCT05379595 ) is a phase Ib/II study evaluating amivantamab monotherapy in chemorefractory (2-3 prior lines) mCRC. Participants had centrally confirmed RAS / BRAF / EGFR ectodomain wild-type status, without ERBB2 / HER2 amplification. Participants with left-sided mCRC without (cohort A) or with (cohort B) prior anti-EGFR antibody treatment, or right-sided mCRC (cohort C) regardless of prior anti-EGFR treatment, received intravenous amivantamab 1,050 mg (1,400 mg for ≥80 kg) once every 2 weeks. The primary end point was objective response rate (ORR) per RECIST v1.1. RESULTS By October 31, 2024, 94 participants received amivantamab monotherapy (median follow-up, 11.9 months). The median age was 60 years, and 65% of participants were male, with a median of 2 prior lines (94%, prior bevacizumab). In left-sided cohorts, the ORR was 29% (5 of 17) in cohort A and 19% (10 of 54) in cohort B; the median duration of response (DoR) was 9.0 months and 6.1 months, and the median progression-free survival (PFS) was 5.7 months and 4.6 months, respectively. In the right-sided cohort, the ORR was 22% (10 of 23; 43% had prior anti-EGFR), the median DoR was 9.8 months, and the median PFS was 3.7 months. Most frequent treatment-related grade ≥3 adverse events (AEs) were rash (7%), dermatitis acneiform (4%), and hypoalbuminemia (4%). One participant discontinued amivantamab because of a treatment-related AE. CONCLUSION Amivantamab monotherapy demonstrated promising, durable antitumor activity in chemorefractory mCRC, regardless of prior anti-EGFR therapy and the primary tumor location. The amivantamab safety profile in mCRC is consistent with experience in NSCLC. Amivantamab plus chemotherapy is currently being explored in two phase III studies in first-line and second-line mCRCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- NYU Langone Health, New York, NY.
- UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA.
- MD Anderson Cancer Center, Houston, TX.
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany.
- START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
ORCID-Profile: Paul E Oberstein, J Randolph Hecht, Kanwal Raghav, Filippo Pietrantonio, Dirk Arnold, Victor Moreno, Eric Van Cutsem, Rozita Abdul Malik, Yong Sang Hong, Myung Ah Lee, Harvey Yu-Li Su, Jeeyun Lee, Ying Yuan, Hung-Chih Hsu, Eric Xueyu Chen, Elena Elez, Chia-Chi Lin, Carlos Lopez, Hans Prenen, Susana Roselló-Keränen, Yu-Min Yeh, Volker Heinemann, Cathy Eng, Seung-Hoon Beom, Sabine Tejpar, Emrullah Yilmaz, Mahadi Baig, Sae-Won Han
Zitieren
APA
Oberstein, P. E., Hecht, J. R., Raghav, K., Pietrantonio, F., Arnold, D., Moreno, V., Van Cutsem, E., Malik, R. A., Hong, Y. S., Lee, M. A., Yu-Li Su, H., Lee, J., Chandana, S., Cruz-Correa, M., Yuan, Y., Ahmad, A., Lai, K. M., Hsu, H. C., Chen, E. X., …, & Han, S. W. (2026). Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. Journal of Clinical Oncology, 44(17), 1624-1634. https://doi.org/10.1200/jco-25-02187
Vancouver
Oberstein PE, Hecht JR, Raghav K, Pietrantonio F, Arnold D, Moreno V, et al. Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. Journal of Clinical Oncology. 2026;44(17):1624-1634. doi:10.1200/jco-25-02187
BibTeX
@article{Oberstein2026,
author = {Oberstein, Paul E and Hecht, J Randolph and Raghav, Kanwal and Pietrantonio, Filippo and Arnold, Dirk and Moreno, Victor and Van Cutsem, Eric and Malik, Rozita Abdul and Hong, Yong Sang and Lee, Myung Ah and Yu-Li Su, Harvey and Lee, Jeeyun and Chandana, Sreenivasa and Cruz-Correa, Marcia and Yuan, Ying and Ahmad, Azura and Lai, Kuan-Ming and Hsu, Hung-Chih and Chen, Eric Xueyu and Elez, Elena and Lin, Chia-Chi and Lopez, Carlos and Prenen, Hans and Roselló-Keränen, Susana and Velez, Hector and Yeh, Yu-Min and Heinemann, Volker and Eng, Cathy and Beom, Seung-Hoon and Tejpar, Sabine and Chowdhury, Sanjib and Lyu, Xuesong and Kamat, Medha and Curtin, Joshua C and Patel, Bharvin and Xie, John and Bhattacharya, Rianka and Schnepp, Robert W and Yilmaz, Emrullah and Iwasawa, Ryota and Daksh, Mahesh and Lorenzini, Patricia and Thayu, Meena and Baig, Mahadi and Kim, Han Sang and Han, Sae-Won},
title = {Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {17},
pages = {1624--1634},
doi = {10.1200/jco-25-02187}
}
EUVIMED